tiprankstipranks
Altamira Therapeutics Transitions to OTCQB Following Nasdaq Delisting
Company Announcements

Altamira Therapeutics Transitions to OTCQB Following Nasdaq Delisting

Story Highlights

Don't Miss Our New Year's Offers:

Altamira Therapeutics ( (CYTO) ) just unveiled an announcement.

Altamira Therapeutics announced its transition from Nasdaq to the OTCQB marketplace after failing to comply with Nasdaq’s minimum bid price requirement. The move ensures that trading of its shares continues uninterrupted under the ticker ‘CYTOF’, with no reverse stock split needed. Altamira’s CEO expressed disappointment but emphasized the opportunities presented by joining the OTCQB, a large marketplace for emerging growth companies, which aligns with their focus on expanding their RNA delivery platforms.

More about Altamira Therapeutics

Altamira Therapeutics is a company focused on developing and supplying peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues, with its proprietary platforms OligoPhore™ and SemaPhore™. The company is working on preclinical siRNA programs for KRAS driven cancer and rheumatoid arthritis and offers its versatile delivery platform for licensing. Altamira is also involved in the commercialization of Bentrio®, a nasal spray for allergic rhinitis, and is headquartered in Hamilton, Bermuda, with main operations in Basel, Switzerland.

YTD Price Performance: -91.38%

Average Trading Volume: 124,674

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.13M

See more data about CYTO stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAltamira Therapeutics announces transition from Nasdaq to OTC markets
TheFlyAltamira Therapeutics provides update on Nasdaq listing
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App